Trial · NCT05730673
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
NCT05730673, Phase 2, Withdrawn, CytoDyn, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer. Trials, record NCT05730673. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05730673
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
- NCT number
- NCT05730673
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- CytoDyn, Inc.
- Conditions
- CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
- Interventions
- 700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3
- First posted
- 2023-02-16
- Last updated
- 2023-02-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)) in subjects with CCR5+ mCRC treated with Leronlimab (PRO 140) and Regorafenib. | Four weeks | |
| Secondary | The number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of Leronlimab (PRO 140) and Regorafenib in subjects with CCR5+ mCRC. | Four weeks | |
| Secondary | Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first. | Four weeks | |
| Secondary | Overall survival defined as time in months from the date of first study treatment to the date of death; | Four weeks | |
| Secondary | Time to new metastases (TTNM) | Four weeks | |
| Secondary | The change from baseline in circulating tumor cells (CTC) in the peripheral blood. | Four weeks | |
| Other | Measure serum level of CCL2, CCL3, CCL4 and CCL5 and correlate with therapeutic benefit (PFS) in patient with mCRC. | Four weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05730673
GET https://conductscience.org/api/trials/v1/NCT05730673/registered